Immuno-oncology is an emerging field that has taken great strides in the fight against cancer, bolstered by a refined understanding of how tumors evade the natural immune response. Leading immuno-oncology researchers are leveraging next-generation sequencing (NGS) to study immunotherapy response factors, discover biomarkers, and apply genomics to personalized immunotherapy.
Research into the mechanisms tumors use to evade the immune response have led to promising therapeutic targets. These therapies boost the ability of the immune system to target cancer, or limit the tumor’s ability to evade the immune response. In addition, NGS can help identify which pathways are activated in the tumor environment and involved in processes such as cancer cell proliferation, survival, invasion, and metastasis.
Listen to Dr. Guo-Liang Chew of the Cancer Science Institute of Singapore discuss a novel role for developmental genes in regulating the immune response to cancer.Listen to Podcast
RNA-Seq and HLA typing using NGS are powering the Immatics target discovery platform.Read Interview
High-throughput sequencing has shown remarkable utility in cancer and immunology research, as well as in the development of individualized immunotherapy.Read Review
Swetha Anandhan from MD Anderson Cancer Center studies the mechanisms that bolster the ability of malignant cells to evade checkpoint blockade immunotherapy. Her talk highlights the use of single cell RNA-sequencing to identify a unique population of macrophages in glioblastoma multiforme that persists after treatment with immune checkpoint inhibitors.View Webinar
Transcriptome analysis is helping to advance cancer immunotherapy research. This white paper demonstrates the performance of Illumina TruSeq RNA Exome compared to a hybridization-based digital counting method (Nanostring Technologies) for quantitative analysis of 57 tumor tissue samples.Read White Paper
Illumina offers several library preparation and sequencing options with access to data analysis options for immuno-oncology research. Streamlined workflows and flexible kit configurations accommodate multiple study designs.
Approximately 90% of the world’s sequencing data are generated using Illumina sequencing by synthesis (SBS) chemistry.*
Click on the below to view products for each workflow step.
Assay targeting multiple variant types, including tumor mutational burden and microsatellite instability, even from low-quality samples.TruSeq RNA Exome
The TruSeq RNA Exome library prep kit provides a low-cost solution for analyzing human RNA isolated from limited or low-quality samples, including FFPE.TruSeq DNA Exome
TruSeq DNA Exome is a cost-effective library preparation and exome enrichment solution.
Targeted RNA expression research panel investigating 395 genes involved in tumor-immune system interactions.Illumina DNA Prep with Enrichment
On-bead tagmentation chemistry is combined with a simplified, single hybridization protocol to reduce total workflow time.TruSeq Stranded Total RNA Library Prep Kit
A robust, highly scalable whole-transcriptome analysis solution for a variety of species and sample types.
Flexible configurations that support up to 12 exomes per run.NextSeq 1000 & 2000 Systems
These cost-efficient, user-friendly, mid-throughput benchtop sequencers offer extreme flexibility to support both current and emerging applications.
Flexibility and high throughput for virtually any genome, sequencing method, and scale of project.
User-friendly data analysis apps for RNA-Seq and other common methods.DRAGEN Bio-IT Platform
Accurate, ultra-rapid analysis of NGS data, on-premise or in the cloud.
Uses the Isaac Genome Alignment Software and the Isaac Variant Caller for exome data analysis.
*Data calculations on file. Illumina, Inc., 2015